Quick Answer
Viridian Therapeutics, Inc.DE reported Operating Income of -$363.39 million for fiscal year 2025.
Viridian Therapeutics, Inc.DE Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$363.39M | -21.5% |
| 2024 | -$299.04M | -17.5% |
| 2023 | -$254.45M | -89.5% |
| 2022 | -$134.30M | -68.5% |
| 2021 | -$79.73M | +27.8% |
| 2020 | -$110.38M | -162.9% |
| 2019 | -$41.98M | -26.9% |
| 2018 | -$33.08M | -24.7% |
| 2017 | -$26.53M | -56.2% |
| 2016 | -$16.99M | -51.8% |
| 2015 | -$11.19M | -62.9% |
| 2014 | -$6.87M | -3385.8% |
| 2013 | -$197.0K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$40.01M | +52.1% | +62.5% |
| June 30, 2025 | -$106.77M | -47.9% | -13.7% |
| March 31, 2025 | -$93.87M | -67.9% | -12.4% |
| September 30, 2024 | -$83.48M | -63.0% | -15.6% |
| June 30, 2024 | -$72.19M | -21.8% | -29.1% |
| March 31, 2024 | -$55.90M | +22.9% | -9.1% |
| September 30, 2023 | -$51.22M | -72.0% | +13.6% |
| June 30, 2023 | -$59.27M | -100.5% | +18.2% |
- Viridian Therapeutics, Inc.DE showed a decrease of -21.5% in Operating Income compared to the prior fiscal year.
- Over the 2013–2025 period, Viridian Therapeutics, Inc.DE’s operating income has declined by 184364.5% (from -$197.0 thousand to -$363.39 million).
- The most recent figure is from Viridian Therapeutics, Inc.DE’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: